Rosiglitazone increased heart failure but did not differ from metformin plus sulfonylurea for other CV outcomes at interim analysis
- PMID: 17975869
Rosiglitazone increased heart failure but did not differ from metformin plus sulfonylurea for other CV outcomes at interim analysis
Comment on
-
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.N Engl J Med. 2007 Jul 5;357(1):28-38. doi: 10.1056/NEJMoa073394. Epub 2007 Jun 5. N Engl J Med. 2007. PMID: 17551159 Clinical Trial.